Imvax names Furey CEO
Discovery and clinical-stage biotechnology company Imvax has named John Furey as CEO and member of the board of directors. He was previously COO of Spark Therapeutics. Furey has succeeded interim CEO David Andrews, cofounder and chief medical officer.
Bayer names De Backer to business development executive role
Bayer has appointed Marianne De Backer as head of business development and licensing of its pharmaceuticals division, reporting to Stefean Oelrich, president of its pharmaceuticals division. De Backer will lead Bayer’s external pharmaceutical growth strategy.
Ogilvy Health promotes Blomfield
Ogilvy Health has named Dan Blomfield as MD of its Singapore operations, reporting to WPP Health international CEO Claire Gillis and responsible for expanding its business in Singapore. Previously, he was client services director for MIMS, a healthcare provider and medical technology company in Asia.
Piscitelli named Oric CFO
Oric Pharmaceuticals has appointed Dominic Piscitelli as CFO of the clinical stage oncology company. He will lead finance, investor relations and corporate operations. Previously, Piscitelli was CFO of AnaptysBio and VP of finance, strategy and IR at Medication.
Levy joins BlackThorn
BlackThorn Therapeutics has appointed Monique Levy as chief strategy officer. She will lead the company’s corporate development and digital health teams and oversee business development initiatives for the company’s therapeutic pipeline and computational psychiatry platform. Levy will report to president and COO Bill Martin.
Precision completes name change, appoints CEO
Precision IBD has named Mark McKenna as CEO as it changes its name to Prometheus Biosciences. He is succeeding CEO Scott Glenn, who will serve as adviser and member of the board. McKenna is joining Precision from Salix Pharmaceuticals.
Milestone names Hasija CFO
Milestone Pharmaceuticals has named Amit Hasija as CFO and EVP of corporate development. He was most recently CFO and chief business officer at Fulcrum Therapeutics and VP of integrated care at Sanofi.
Harris joins Altimmune
Clinical-stage biopharmaceutical Altimmune has appointed Scott Harris as chief medical officer, succeeding Sybil Tasker, who resigned at the end of June. Previously, he was cofounder and chief medical officer of Lyric Pharmaceuticals and chief medical officer of Avaxia Biologics.
Cerevel brings on Coles
Cerevel Therapeutics has appointed Tony Coles as CEO. He has been serving as executive chair of the board since December, a role he will retain. Previously, he was cofounder and CEO of Yumanity Therapeutics.
Kazmi joins Jubilant
Jubilant Life Sciences has hired Syed Kazmi as president and CEO of its new biopharmaceutical company in the US. He was previously VP and global head of business development and licensing for oncology at Novartis.
Medicx hires Magnano
Healthcare marketing services company Medicx Media Solutions has hired Scott Magnano as CFO. He was previously assistant VP for financial planning and analytics at finance and insurance products provider CNA National Warranty and director of financial planning and analysis at LifeLock.
InkHouse hires healthcare practice leader
InkHouse has hired Brendan Monahan as VP, leading its healthcare practice. The firm’s healthcare clients include connectRN, Harvard Pilgrim Health Care and Maven Clinic.
Client-side people moves courtesy of MM&M sister brand The PMD.
The Escalator is a weekly roundup of notable people moves in the pharmaceutical and healthcare marketing industries. For submissions, email Frank Washkuch at firstname.lastname@example.org.